Q1 EPS Estimate for Aytu BioPharma Reduced by Analyst

Aytu BioPharma Inc. (NASDAQ:AYTU) – Investment analysts at Ascendiant Capital Markets lowered their Q1 2027 EPS estimates for Aytu BioPharma in a research note issued on Tuesday, September 29th. Ascendiant Capital Markets analyst E. Woo now expects that the company will post earnings of ($0.10) per share for the quarter, down from their previous forecast of ($0.01). Ascendiant Capital Markets currently has a “Buy” rating and a $14.50 target price on the stock. The consensus estimate for Aytu BioPharma’s current full-year earnings is ($0.16) per share. Ascendiant Capital Markets also issued estimates for Aytu BioPharma’s Q2 2027 earnings at ($0.09) EPS, Q3 2027 earnings at ($0.04) EPS, Q4 2027 earnings at $0.06 EPS and FY2027 earnings at ($0.16) EPS.

AYTU has been the topic of a number of other reports. Zacks Research upgraded Aytu BioPharma from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 13th. Citigroup reiterated a “positive” rating on shares of Aytu BioPharma in a research report on Tuesday, September 22nd. Finally, Weiss Ratings raised Aytu BioPharma from a “sell (d-)” rating to a “sell (d)” rating in a report on Tuesday, September 22nd. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $14.50.

Aytu BioPharma Price Performance

Shares of AYTU opened at $2.05 on Tuesday. The firm has a market cap of $22.28 million, a PE ratio of -1.23 and a beta of 0.17. The company has a current ratio of 1.13, a quick ratio of 1.00 and a debt-to-equity ratio of 0.26. The firm has a fifty day simple moving average of $2.22 and a two-hundred day simple moving average of $2.30. Aytu BioPharma has a 1-year low of $1.80 and a 1-year high of $3.07.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in AYTU. Nantahala Capital Management LLC purchased a new stake in shares of Aytu BioPharma in the 2nd quarter worth $2,336,646. Stonepine Capital Management LLC purchased a new position in Aytu BioPharma during the second quarter valued at $1,962,780. AWM Investment Company Inc. purchased a new position in Aytu BioPharma during the second quarter valued at $1,332,000. Crown Advisors Management Inc. bought a new stake in Aytu BioPharma during the second quarter valued at about $430,000. Finally, Arete Wealth Advisors LLC bought a new stake in Aytu BioPharma during the first quarter valued at about $135,000. 33.49% of the stock is currently owned by institutional investors.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on commercializing prescription medicines, primarily for pediatric and primary-care markets. The company’s activities include acquiring, developing and commercializing products intended to address unmet needs in areas such as attention deficit hyperactivity disorder (ADHD), allergies and other common medical conditions.

Aytu’s ADHD portfolio has included Adzenys XR-ODT, an orally disintegrating extended-release amphetamine tablet; Cotempla XR-ODT, an orally disintegrating extended-release methylphenidate tablet; and Dyanavel XR, an extended-release liquid amphetamine formulation.